AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

Rhea-AI Summary

AtaiBeckley (NASDAQ: ATAI) was added to the S&P Total Market Index, S&P Completion Index and CRSP U.S. benchmark indices, effective March 23, 2026. Inclusion in CRSP triggers mandatory position-building by passive index funds tracking more than $3 trillion in assets.

The company said its BPL-003 Phase 3 program remains on track to initiate in Q2 2026, with topline VLS-01 Phase 2b data expected in H2 2026. These additions follow inclusion in the Nasdaq Biotechnology Index in December 2025.

Positive

• Mandatory passive demand from funds tracking >$3 trillion in AUM
• Broader index coverage via S&P Total Market and S&P Completion indices
• BPL-003 Phase 3 on track to initiate in Q2 2026
• VLS-01 topline data expected in H2 2026

Negative

• Quarterly reconstitutions of CRSP indices may drive periodic passive trading flows

News Market Reaction – ATAI

-0.29%

18 alerts

-0.29% Session close to close

+2.8% Peak in 28 hr 37 min

$1.33B Market Cap

0.3x Rel. Volume

In the Mar 24 session, ATAI declined 0.29%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement combines a structural market catalyst with pipeline visibility. Joining CRSP and S...

Analysis

This announcement combines a structural market catalyst with pipeline visibility. Joining CRSP and S&P benchmarks tied to over $3 trillion in indexed assets hardwires ATAI into major passive strategies, while reiterating BPL-003 Phase 3 initiation in Q2 2026 and VLS-01 data in H2 2026. Recent history shows mixed price reactions to positive clinical news, so investors may watch how index flows, future trial readouts, and any further use of the effective S-3ASR shelf interact.

Key Figures

CRSP-tracking AUM: $3 trillion S&P Completion breadth: approximately 3,000 companies Index inclusion effective: March 23, 2026 +2 more

5 metrics

CRSP-tracking AUM $3 trillion Assets tracking CRSP U.S. benchmark indices referenced in the release

S&P Completion breadth approximately 3,000 companies Number of mid-, small-, and micro-cap constituents not in S&P 500

Index inclusion effective March 23, 2026 Effective date for S&P and CRSP index additions

BPL-003 Phase 3 timing Q2 2026 Planned initiation of BPL-003 Phase 3 program

VLS-01 topline timing H2 2026 Expected VLS-01 Phase 2b topline data window

Previous Clinical trial Reports

5 past events · Latest: Mar 17 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 17	BPL-003 Phase 2a data	Positive	+0.0%	Peer-reviewed Phase 2a TRD data with durable antidepressant effects and safety.
Mar 10	BPL-003 Phase 3 plans	Positive	+6.4%	Phase 3 program on track after FDA meeting; cash runway into early 2029.
Mar 03	End-of-Phase 2 meeting	Positive	+0.3%	Successful FDA End-of-Phase 2 meeting and support for dual pivotal Phase 3.
Feb 26	EMP-01 Phase 2a SAD	Positive	-14.1%	Positive EMP-01 Phase 2a social anxiety data with significant LSAS reduction.
Nov 10	BPL-003 Phase 2b OLE	Positive	-0.2%	Phase 2b OLE showed added benefit from second BPL-003 dose with sustained effect.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinical trial updates have mostly been positive but produced mixed to negative next-day moves, with more divergences than alignments.

Recent Company History

Over the past several months, AtaiBeckley has repeatedly highlighted advancement of its mental health pipeline. Multiple updates on BPL-003 moved the program toward dual pivotal Phase 3 in Q2 2026, while EMP-01 and VLS-01 delivered positive Phase 2 readouts. Despite these clinically constructive milestones and reaffirmed runway into early 2029, next-day stock reactions to clinical news skewed modestly negative. Today’s index inclusion and Phase 3 timing reference extend that narrative of operational progress against a volatile trading backdrop.

Key Terms

crsp u.s. benchmark indices, s&p total market index, s&p completion index, nasdaq biotechnology index, +4 more

8 terms

crsp u.s. benchmark indices financial

"its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 23, 2026."

CRSP U.S. benchmark indices are a family of standardized stock‑market “yardsticks” created by the Center for Research in Security Prices to track different segments of the U.S. equity market by company size and trading behavior. Investors and fund managers use these indices to measure performance, compare investment results, and construct index funds or ETFs; think of them as a common ruler that shows whether a portfolio is outperforming or lagging the market.

s&p total market index financial

"its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 23, 2026."

S&P Total Market Index is a broad stock-market benchmark that measures the collective performance of most publicly traded companies across large, mid and small sizes in a given market. Investors use it as a single, diversified snapshot of overall market health and a common basis for index funds and ETFs—like checking the temperature of an entire economy rather than watching one company—so it helps spread risk and track broad market trends.

s&p completion index financial

"its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 23, 2026."

A broad stock-market benchmark made up of all U.S.-listed companies that are not in the S&P 500, the S&P Completion Index captures the performance of the mid- and small-cap portion of the market. For investors it acts like the “rest of the market” gauge—useful for comparing how smaller companies are doing, for diversifying beyond the largest firms, and for measuring or building investment strategies that target growth outside the biggest names.

nasdaq biotechnology index financial

"building on its addition to the Nasdaq Biotechnology Index in December 2025"

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

s&p 500 financial

"micro-cap companies not included in the S&P 500®Continues a series of index inclusions"

The S&P 500 is a broad stock market index that tracks the performance of 500 large U.S. companies, weighted so bigger firms have a larger impact. Investors use it like a thermometer or benchmark to judge how the overall U.S. stock market or a portfolio is doing; movements in the index influence investor sentiment, fund performance, and many passive investment products that aim to match its returns.

View in glossary

assets under management (aum) financial

"passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fund"

Assets under management (AUM) is the total value of all the investments that a financial company or fund is responsible for overseeing on behalf of its clients. It’s like a bank counting all the money it manages for people and organizations—more AUM generally means the company is trusted with larger amounts and can charge higher fees.

phase 3 medical

"BPL-003 Phase 3 program remains on track to initiate in Q2 2026"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2b medical

"topline data from the VLS-01 Phase 2b study are expected in H2 2026."

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Inclusion in U.S. CRSP^® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fund
• Expands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500^®
• Continues a series of index inclusions across the U.S. equity benchmark landscape, reflecting AtaiBeckley’s enhanced eligibility following its U.S. re-domiciliation and building on its addition to the Nasdaq Biotechnology Index in December 2025
  
  

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its addition to the S&P Total Market Index, the S&P Completion Index and CRSP^® U.S. benchmark indices, effective March 23, 2026. BPL-003 Phase 3 program remains on track to initiate in Q2 2026, and topline data from the VLS-01 Phase 2b study are expected in H2 2026.

Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said: "Being added to the S&P Total Market Index, S&P Completion Index, and CRSP U.S. benchmark indices reflects meaningful recognition of AtaiBeckley's enhanced presence in U.S. equity markets, with the CRSP index alone tracking more than $3 trillion in passively managed assets. These inclusions broaden our reach across index-tracking strategies and build on our earlier addition to the Nasdaq Biotechnology Index in December 2025. We see these additions as a natural progression as AtaiBeckley’s market profile grows alongside our advancing clinical pipeline, including BPL-003’s anticipated Phase 3 initiation in the second quarter."

The S&P Total Market Index tracks virtually all U.S.-listed common stocks traded on the NYSE, NYSE American, NASDAQ National Market, and NASDAQ Small Cap exchanges, providing comprehensive coverage of the investable U.S. equity universe. The S&P Completion Index comprises all members of the S&P Total Market Index that are not current constituents of the S&P 500^®, offering broad exposure to approximately 3,000 mid-, small-, and micro-cap U.S. companies. These indexes are widely used by institutional investors and asset managers as benchmarks for passive investment strategies.

The CRSP^® benchmark indices are maintained by the Center for Research in Security Prices, formerly a research center of the University of Chicago Booth School of Business and acquired by Morningstar, Inc. in February 2026, and serve as the basis for index funds representing more than $3 trillion in assets, including the world’s largest mutual fund. CRSP indexes are reconstituted quarterly and are routinely adopted by institutional investors, including Vanguard, as the basis for broad-market passive strategies.

About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; the expected impact of the inclusion on the indices; the potential, success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones; and the plans and objectives of management for future operations, research and development and capital expenditures.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our quarterly reports and other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information:
Investors:
Jason Awe, PhD
VP, Investor Relations
IR@ataibeckley.com

Media:
Charlotte Chorley
Associate Director, Communications
PR@ataibeckley.com

FAQ

What does AtaiBeckley (ATAI) joining the CRSP index mean for shareholders on March 24, 2026?

It means mandatory position-building by passive funds tracking CRSP, which represent more than $3 trillion in assets. According to the company, this inclusion broadens passive-investor exposure and can increase demand from index-tracking strategies.

How does addition to the S&P Total Market and Completion indices affect ATAI's market presence?

Addition expands exposure across virtually all U.S.-listed equities and non-S&P 500 companies. According to the company, these inclusions increase accessibility to institutional and passive investors tracking broad-market benchmarks.

When will AtaiBeckley's BPL-003 Phase 3 program start and what is the timeline?

BPL-003 Phase 3 is on track to initiate in Q2 2026, per the company. This initiation aligns with the firm's stated timeline as its pipeline advances following index inclusions and U.S. re-domiciliation.

When are topline results for VLS-01 Phase 2b expected for ATAI investors?

Topline data for VLS-01 Phase 2b are expected in H2 2026, according to the company. These results represent a near-term clinical readout that the company highlights alongside its index inclusions.

Did AtaiBeckley previously join other indices before March 23, 2026?

Yes. The company was added to the Nasdaq Biotechnology Index in December 2025, as noted by the company. That prior inclusion is cited as a precursor to these broader U.S. index additions.